Commercial

OPM Cuts Staff, Executive Wages in Wake of Servier Exit

The French biotech company Oncodesign Precision Medicine has been forced to tighten its purse strings as a result of the decision made by Servier...

Eli Lilly provides a $1.4 billion gene therapy contract to struggling Sangamo

Through its licensing deal with Eli Lilly, Sangamo Therapeutics received $18 million to let the pharma use its neurotropic adeno-associated virus capsid in central...

Opko & Entera Enter Partnership to Develop Obesity Pill

Opko Health and Entera Bio have formally announced their collaboration as the biopharmaceutical companies seek to advance the first orally given dual agonist glucagon-like...

Roche Expands Obesity Pipeline with $1.65 Billion Zealand Pharma Partnership

Roche has committed to an initial payment of $1.65 billion to enhance its growing pipeline of obesity treatments. This investment, supplemented by potential milestone...

Mallinckrodt & Endo Engage in $6.7B Merger

After almost a decade of contending with bankruptcy filings and opioid settlements, struggling pharmaceutical companies Mallinckrodt and Endo have opted to collaborate in order...

Hologen AI Commits Up to $430 Million to Advance MeiraGTx’s Parkinson’s Gene Therapy to Phase 3 and Beyond

Hologen AI has pledged up to $430 million through a strategic partnership to support MeiraGTx in advancing its gene therapy for Parkinson’s disease through...

Amgen and CytomX remove disguised T-cell engager and axe the asset

The phase 1 T-cell engager developed by Amgen and CytomX Therapeutics was terminated because both organizations evaluated clinical outcomes and their research strategies. The...

Teleflex Restructures Amidst €760 Million Biotronik Deal, Paving the Way for Two Independent Businesses

Teleflex has announced plans to restructure its operations by creating two independent businesses, a move driven in part by its recent €760 million ($791...

Latest news

Pfizer Decides Against Pursuing Lead Obesity Asset Amid Liver Safety Concerns

Pfizer said that it had discovered a possible instance of medication-induced liver impairment and, as a result, would no...

Vanda Challenges FDA Over Limits on Off-Label Drug Communication

Vanda Pharmaceuticals is pushing back against the U.S. Food and Drug Administration (FDA), accusing the agency of stifling the...

Life Sciences Voice Top Five Newsletter

Welcome to this week’s edition of the Life Sciences Voice Top Five Newsletter, your go-to source for the latest...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you

Six Things to Know in August 2022 1st Week

Monkeypox in pet dog, a hope for...

Algernon Pharmaceuticals Starts both Repirinast Production and CKD Research Program

Vancouver-based Algernon Pharmaceuticals has granted a contract...